Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

1.025 -0.025 (-2.38%)
Streaming Delayed Price Updated: 1:21 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025
Via ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025
Via ACCESS Newswire
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review
From RenovoRx, Inc.
Via Business Wire
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
From RenovoRx, Inc.
Via Business Wire
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
From RenovoRx, Inc.
Via Business Wire
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
From RenovoRx, Inc
Via Business Wire
BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering
Via Investor Brand Network
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Proposed Public Offering
From RenovoRx, Inc.
Via Business Wire
RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
From RenovoRx, Inc.
Via Business Wire
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
From RenovoRx, Inc.
Via Business Wire
RenovoRx CEO Issues Update Letter to Shareholders
From RenovoRx, Inc.
Via Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
From RenovoRx, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.